SEER and CDC cancer statistics show a sharp survival gap by stage at diagnosis. Localized and regional prostate cancer have about 100 percent five-year relative survival, while distant disease is about 40 percent.
Most prostate cancers are found before they have spread far from the prostate. In the SEER data, 69% are diagnosed at a localized stage and 14% at a regional stage. Those two groups have 100% five-year relative survival. The picture changes when prostate cancer is first found after distant spread. SEER reports 40.1% five-year relative survival for distant prostate cancer, and CDC describes the same broad pattern in U.S. Cancer Statistics.
These figures are population statistics. They help explain why screening decisions, PSA follow-up, referrals, biopsy timing, and communication of abnormal results can matter, but they do not predict any one person's outcome.
Five-year relative survival by stage
SEER 21 excluding Illinois, cases diagnosed from 2016 to 2022.
| Localized | 100% |
|---|---|
| Regional | 100% |
| Distant | 40.1% |
Relative survival estimates the share of patients expected to survive the effects of cancer after accounting for other causes of death. SEER cautions that survival statistics are based on large groups and cannot predict exactly what will happen to an individual patient.
How prostate cancer is usually found
Share of prostate cancers by stage at diagnosis in SEER.
| Localized | 69% |
|---|---|
| Regional | 14% |
| Distant | 9% |
| Unknown | 8% |
SEER reports 69% localized, 14% regional, 9% distant, and 8% unknown or unstaged. CDC U.S. Cancer Statistics reports a similar stage distribution for 2019 to 2023, with 70% localized, 14% regional, and 9% distant.
Why PSA follow-up matters
PSA screening is not a simple yes or no rule. NCI explains that PSA can rise because of prostate cancer or benign conditions such as BPH or prostatitis, and that PSA testing is used to monitor known cancer, evaluate symptoms, and screen some men without symptoms. USPSTF recommends that men ages 55 to 69 make an individual PSA screening decision after discussing benefits and harms with a clinician, and recommends against routine PSA screening for men 70 and older.
The American Cancer Society also emphasizes follow-up after screening choices are made. Its guidance says men who choose screening and have PSA of 2.5 ng/mL or higher should generally be screened yearly, while some lower borderline abnormal results may be repeated after about a month and higher values may warrant other tests or biopsy. The medical reason is the survival gap shown above. Catching prostate cancer before distant spread can preserve earlier-stage treatment options, even though PSA is imperfect and not every cancer behaves the same way.
When advanced disease raises questions about timing
An advanced or late prostate cancer diagnosis can sometimes follow a missed PSA result, a rising PSA that was not repeated, a delayed urology referral, a delayed biopsy, a lost imaging result, or a failure to communicate an abnormal result. That is only one possible reason for a late diagnosis. Many advanced cancers are diagnosed promptly and progress despite appropriate care.
Certain prostate cancer medications are used mainly for metastatic, castration-resistant, bone-metastatic, PSMA-positive, or biomarker-selected advanced disease. Those medications can sometimes be a reason to ask timeline questions, but they do not prove when the cancer should have been diagnosed and they never prove negligence by themselves. If there was an earlier abnormal PSA, abnormal DRE, concerning symptom, imaging finding, or biopsy recommendation, it may be worth having your questions reviewed with the medical records.
New York timing rules can be strict. CPLR 214-a generally sets a medical malpractice limitations period of two years and six months, with a special cancer diagnosis rule that may depend on when the person knew or reasonably should have known of the alleged negligent act or omission and injury, subject to a seven-year cap. The exact deadline depends on the records and should be reviewed by a licensed New York attorney.
If you or someone you love was diagnosed with advanced prostate cancer, the team at Porter Law Group can review the medical records and the timeline at no cost. There is no obligation.
Methodology and sources
Survival and stage distribution figures come from SEER Cancer Stat Facts for Prostate Cancer. The survival chart uses SEER 21 excluding Illinois, cases diagnosed from 2016 to 2022, by SEER Combined Summary Stage. The stage distribution chart uses the SEER percentages shown with those survival data. CDC U.S. Cancer Statistics is used as a federal cross-check for recent stage distribution and overall survival language. Screening and follow-up context is drawn from USPSTF, NCI, and the American Cancer Society. New York timing background is drawn from CPLR 214-a. This report presents aggregate public statistics only and does not evaluate any individual diagnosis, provider, or medical record.
